PATENT CLAIM ANALYSIS

Application Number: 16000678
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-06
Patent Classification: ["514", "275000"]

Abstract:
Disclosed herein is a method for modulating Program Death Receptor Ligand 1 (PDL1) in a cancer cell, comprising contacting the cell with a composition comprising a histone deacetylase (HDAC) inhibitor. Also disclosed is a method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a histone deacetylase (HDAC) inhibitor and a composition comprising a therapeutically effective amount of a Program Death Receptor Ligand 1 (PDL1) inhibitor, a Programmed Death 1 receptor (PD1) inhibitor, or a combination thereof.

Claim (Index 2):
The method  claim 1 , wherein the HDAC inhibitor comprises a selective inhibitor of histone deacetylase 6 (HDAC6).

Metadata:
- Claim Count in Document: 7.0
- Percentile: 94.0
- Lexical Diversity: 2.21277
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15120065', '15695435', '14907321', '15231187', '15120053']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7646002282375725
- 35 USC 102 Novelty (BERT): 0.6179398288540704
- Combined Prediction Score: 0.7499341882992223
- Mean Citation Score: 395.918044
- Max Citation Score: 555.71234
- Similarity Product: 495.40025876500846

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test